Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.00
Nov 16 • 3:59 PM ET Dollar change-0.04 Percentage change(-3.85%)
Aftermarket Close
0.9800
Aftermarket • 7:30 PM ET Dollar change-0.0200 Percentage change(-2.00%)
Nov 16, 10:16 AMAlx Oncology Holdings Inc reports fiscal Q3 2026 results with non-GAAP EPS $-0.15 (+63% YoY) and revenue $0, misses EPS but beats revenue estimates
Index
RUT
Market Cap
138.28M
Enterprise Value
11.09M
Income
-80.89M
Sales
0.00M
Book/sh
0.99
Cash/sh
1.00
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
43
IPO
Jul 17, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.01
P/C
1.00
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.71
Current Ratio
9.71
Debt/Eq
0.08
LT Debt/Eq
0.07
Option/Short
Yes / Yes
EPS (ttm)
-1.14
EPS next Y
-0.59
EPS next Q
-0.16
EPS this Y
67.28%
EPS next Y
4.42%
EPS next 5Y
30.69%
EPS past 3/5Y
14.52% -8.19%
Sales past 3/5Y
- -
EPS Y/Y TTM
48.20%
Sales Y/Y TTM
-
EPS Q/Q
72.71%
Sales Q/Q
-
Insider Own
22.98%
Insider Trans
-0.01%
Inst Own
64.51%
Inst Trans
13.19%
ROA
-63.16%
ROE
-80.65%
ROIC
-55.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-15.11%
SMA50
-24.83%
SMA200
-44.75%
Trades
Shs Outstand
138.22M
Shs Float
106.50M
52W High
2.66 -62.41%
52W Low
0.86 16.05%
Volatility
14.98% 13.11%
ATR (14)
0.15
RSI (14)
39.12
Beta
0.57
Rel Volume
0.65
Avg Volume
1.15M
Volume
752,606
Perf Week
-22.18%
Perf Month
-5.66%
Perf Quarter
-51.92%
Perf Half Y
-50.00%
Perf YTD
-11.50%
Perf Year
-27.54%
Perf 3Y
-88.80%
Perf 5Y
-97.77%
Perf 10Y
-
Prev Close
1.04
Price
1.00
Change %
-3.85%
Consensus
Strong Buy
Avg. Price Target
$4.75
Implied Upside
+375.0%
Analysts8incl. previous ratings
Rating Distribution7 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 19, 2026Initiated
WFC logoWWells Fargo
Overweight$5+400.0%
Mar 06, 2026Resumed
UBS logoUUBS
Buy$6+500.0%
Nov 13, 2025Initiated
JEF logoJJefferies
Buy$4+300.0%
Mar 06, 2025Upgrade
JEF logoJJefferies
Hold → Buy$2 → $3+200.0%
Dec 19, 2024Downgrade
JEF logoJJefferies
Buy → Hold$12 → $2+100.0%
Mar 08, 2024Downgrade
SF logoSStifel
Buy → Hold$10 → $14+1,300.0%
Dec 08, 2023Upgrade
JEF logoJJefferies
Hold → Buy$8 → $18+1,700.0%
Dec 22, 2021Downgrade
JEF logoJJefferies
Buy → Hold$65 → $25+2,400.0%
Sep 30, 2021Initiated
SF logoSStifel
Buy$106+10,500.0%
May 05, 2021Resumed
CCredit Suisse
Outperform$98+9,700.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lettmann JasonCHIEF EXECUTIVE OFFICERAug 17 '26Sale1.932,2304,304294,379Aug 18 05:51 PM
Wong ShellySVP, FINANCE AND CAOAug 17 '26Sale1.935731,10687,828Aug 18 05:50 PM
Wong ShellySVP, FINANCE AND CAOJul 01 '26Sale2.041,4042,86488,401Jul 06 04:30 PM
Lettmann JasonCHIEF EXECUTIVE OFFICERMar 19 '26Sale2.1712,31126,715293,609Mar 23 04:05 PM
Pinto ShellySVP, FINANCE AND CAOMar 19 '26Sale2.179031,96086,805Mar 23 04:05 PM
Pinto ShellySVP, FINANCE AND CAOFeb 18 '26Sale2.275651,28387,708Feb 20 04:01 PM
GOODMAN COREY SDirectorFeb 02 '26Buy1.573,184,7134,999,9998,453,038Feb 04 04:15 PM
Pinto ShellySVP, FINANCE AND CAOJan 06 '26Sale1.113,9254,35788,273Jan 07 04:30 PM
ALX Oncology Holdings, Inc. is a clinical-stage biotechnology company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
CEO & DirectorMr. Jason W. Lettmann
Chief Financial OfficerMr. Harish Shantharam C.F.A.
Senior VP of Finance & Chief Accounting OfficerMs. Shelly Wong C.P.A.
Chief Medical OfficerDr. Barbara J. Klencke M.D.
Chief Development & Operating OfficerMr. Jeff E. Knight M.P.H.